The firm’s CEO cited a “very competitive” recruiting market in 2024, but forecasts a better 2025 as longer-term efforts pay off.
Edwards Lifesciences (NYSE:EW) traded higher on Thursday after Stifel upgraded the heart device maker to Buy from Hold, citing a turnaround in its position in the market for transcatheter aortic valve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback